BIO Generic Biologics Position: All Products Need "Rigorous" Clinical Trials
Executive Summary
The Biotechnology Industry Organization position statement on generic biologics is firmly against any shortcuts to market for follow-on products.
You may also be interested in...
Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says
FDA's analysis of manufacturing process changes for Xigris is the latest indication that some form of a generic biologics approval process is feasible, the Generic Pharmaceutical Association says
Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says
FDA's analysis of manufacturing process changes for Xigris is the latest indication that some form of a generic biologics approval process is feasible, the Generic Pharmaceutical Association says
J&J Eprex EU Label Changed; FDA Investigating Manufacturing Fraud
Johnson & Johnson is recommending intravenous administration of Eprex (epoetin alfa) over subcutaneous administration in chronic renal failure patients in order to decrease the incidence of pure red blood cell aplasia in a July 17 "Dear Doctor" letter to physicians in the EU